Open AccessClinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
Author(s) -
Lalit Verma,
Mithun Thulasidas,
Ajay Purohit,
Avantika Gupta,
Ritesh Narula,
Dinesh Talwar
Publication year - 2021
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/ijo.ijo_2516_20
Subject(s) - medicine , ranibizumab , macular edema , ophthalmology , adverse effect , visual acuity , intraocular pressure , retrospective cohort study , surgery , bevacizumab , chemotherapy
: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary to retinal vein occlusion (RVO).